Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).

doi:10.1158/1078-0432.CCR-23-1807

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2023

Okuma Hitomi S, Watanabe Keisuke, Tsuchihashi Kenji, Machida Ryunosuke, Sadachi Ryo, Hirakawa Akihiro, Ariyama Hiroshi, Kanai Masashi, Kamikura Masahisa, Anjo Kenta, Hiramitsu Akari, Sekine Shigeki, Okita Natsuko, Mano Hiroyuki, Nishikawa Hiroyoshi, Nakamura Kenichi, Yonemori Kan

Abstract excerpt

PURPOSE: Mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) are positive predictive markers for immune checkpoint inhibitors. However, data on the activity of nivolumab in advanced dMMR/MSI-H rare cancers and more accurate biomarkers are worth exploring. PATIENTS AND METHODS: We conducted a multicenter phase II, open-label, single-arm clinical trial to explore the effectiveness and safety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocytes, Mononuclear

Share to Microsatellite Instability

Share to Neoplasms, Second Primary

Share to Neoplastic Syndromes, Hereditary

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Share to T-Box Domain Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 37819940
DOI: 10.1158/1078-0432.CCR-23-1807
PMCID: PMC10722134

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).PMID 37819940Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR statusSemantic proximity Read ↗

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.Semantic proximity Read ↗

Acquisition Process and Clinical Relevance of dMMR-Associated Mutational Signatures in Hepatocellular Carcinoma.Semantic proximity Read ↗

Real-world Concordance in Microsatellite Instability Status Between PCR-based Testing and Next-Generation Sequencing Assay for Solid TumorsSemantic proximity Read ↗

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumoursSemantic proximity Read ↗

Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists GuidelineSemantic proximity Read ↗

Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity Read ↗

Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical OutcomesSemantic proximity Read ↗

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas CancerSemantic proximity Read ↗

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.